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A B S T R A C T 
Introduction: Studies on the prevalence and 
severity of retinopathy of prematurity in the local 
population are scarce. This study aimed to evaluate 
the prevalence, screening, and treatment outcome of 
retinopathy of prematurity in a tertiary hospital in 
Hong Kong.
Methods: This cross-sectional study with internal 
comparison was conducted at Queen Mary Hospital, 
Hong Kong. The study evaluated 89 premature infants 
who were born at the hospital and were screened 
for retinopathy of prematurity, in accordance with 
the 2008 British Guidelines, between January 2013 
and December 2013. The prevalences of retinopathy 
of prematurity and severe retinopathy requiring 
treatment were studied.
Results: The mean (± standard deviation) gestational 
age at birth was 30+2 weeks ± 16.5 days (range, 24+1 to 
35+5 weeks). The mean birth weight was 1285 g ± 328 g
 (range, 580 g to 2030 g). A total of 15 (16.9%) infants 
developed retinopathy of prematurity and three 
(3.4%) required treatment. In a subgroup analysis of 
extremely-low-birth-weight infants of <1000 g, 70.6% 
developed retinopathy of prematurity and 17.6% 
required treatment. Multivariate logistic regression 
analysis suggested low birth weight and patent 
ductus arteriosus were significantly associated with 
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Introduction
Retinopathy of prematurity (ROP) is a retinal vascular 
disease that affects premature infants in whom the 
retinal vasculature is not fully developed at the time 
of birth. The hyperoxic environment after birth—
inclusive of room air—compared with the relative 
hypoxic intra-uterine environment suppresses the 
growth of retinal vessels (phase 1). Subsequently, 
New knowledge added by this study
• Low birth weight and patent ductus arteriosus were significantly associated with the development of 
retinopathy of prematurity (ROP).
Implications for clinical practice or policy
• ROP is a significant problem among premature infants in Hong Kong, especially those with extremely low birth 
weight.
• Strict adherence to international screening guidelines and vigilance in high-risk infants are key to successful 
ROP management.
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growth of the retina increases metabolic demand 
and, in the background of incomplete retinal 
vascularisation, results in retinal hypoxia and ROP 
development (phase 2).1-3 Retinopathy of prematurity 
is characterised by the presence of abnormal retinal 
fibrovascular proliferation. Severe disease will 
progress to total retinal detachment and blindness if 
there is no intervention during the critical treatment 
ORIGINAL ARTICLE
development of retinopathy of prematurity (P<0.001 
and P=0.035, respectively). Among the three infants 
who received treatment for severe retinopathy of 
prematurity, all regressed successfully after one laser 
treatment.
Conclusions: Retinopathy of prematurity is a 
significant problem among premature infants in 
Hong Kong, especially those with extremely low 
birth weight. Our screening service for retinopathy 
of prematurity was satisfactory and treatment 
results were good. Strict adherence to international 
screening guidelines and vigilance in infants at risk 
are key to successful management of retinopathy of 
prematurity.
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香港一所提供第三層醫療服務的醫院中早產兒視
網膜病變篩查的成效和治療結果
姚沛良、黎匡怡、范靖琰、王逸軒、黎少明
引言：本地有關早產兒視網膜病變的發生率以及其嚴重程度的研究很
少。本研究旨在評估香港一所提供第三層醫療服務的醫院中早產兒視
網膜病變的患病率、篩查成效和治療結果。
方法：這內部比較的橫斷面研究在香港瑪麗醫院內進行。根據2008
年英國皇家兒科學和兒童保健學院的指引，本研究評估2013年1月至
12月期間在上述醫院出生的89名早產兒，並為他們進行視網膜病變篩
查。探討他們視網膜病變的患病率，以及需要治療的嚴重視網膜病變
病例。
結果：早產兒出生時的平均胎齡為30+2週（標準差16.5天；介乎24+1
至35+5週）。平均出生體重為1285 g（標準差328 g；介乎580 g至
2030 g）。共有15名（16.9%）嬰兒出現早產兒視網膜病變，當中3例
（3.4%）需要治療。在極低出生體重嬰兒（<1000 g）的亞組分析中
發現70.6%有早產兒視網膜病變，當中17.6%需要治療。多變量邏輯迴
歸分析顯示低出生體重和開放性動脈導管與早產兒視網膜病變的發展
有關（P值分別為<0.001和0.035）。接受治療嚴重視網膜病變的3例
早產兒在接受一次激光治療後均成功治癒。
結論：視網膜病變是香港早產兒的一個重要問題，特別是出生體重極
低的兒童。我們的早產兒視網膜病變篩查服務令人滿意，治療結果良
好。嚴格遵守國際篩選指南和對處於危險狀態的嬰兒提高警覺是成功
治療早產兒視網膜病變的關鍵。
period. Such retinopathy is one of the leading causes 
of visual impairment in children.4-6
 The risk factors for ROP include low gestational 
age (GA), low birth weight (BW), presence of co-
morbidities (eg patent ductus arteriosus [PDA], 
necrotising enterocolitis (NEC), intraventricular 
haemorrhage [IVH]), and a high level of supplemental 
oxygen.7-9 Those born at extreme prematurity and 
with extremely low birth weight (ELBW) are at 
high risk of severe ROP development. The British 
Guidelines published by the Royal College of 
Paediatrics and Child Health in 2008 recommended 
screening for ROP in premature infants with GA 
of <32 weeks or BW of <1501 g.10 The American 
Guidelines published by the American Academy of 
Pediatrics in 2013 recommended screening for ROP 
if GA was ≤30 weeks or BW ≤1500 g. Selected infants 
with BW of 1500 to 2000 g or GA of >30 weeks with 
an unstable clinical course should also be screened if 
they were assessed by the attending neonatologist to 
be at high risk of ROP.11 Since neonatal intensive care 
units and standards of health care have improved 
significantly in the past decade, more extreme 
preterm infants are surviving and a higher risk of 
ROP development is to be expected.12,13
 The revised International Classification 
of Retinopathy of Prematurity was published in 
2005.14 In this revised version, ROP was classified 
into five stages depending on the severity of retinal 
fibrovascular proliferation and into three zones 
depending on the location of vascularisation.14 Plus 
disease is characterised by the presence of severe 
retinal venous dilatation and arteriolar tortuosity, iris 
vascular engorgement, poor pupillary dilatation, and 
vitreous haze.14 Presence of plus disease indicates 
high disease activity.14 Aggressive posterior ROP is 
an uncommon, severe form of ROP characterised by 
posterior vascularisation, prominent plus disease, 
and rapid progression.14 Timely treatment is required 
for severe ROP to prevent retinal detachment and 
vision loss. Current guidelines suggest treatment if 
the ROP is type 1 pre-threshold defined by the Early 
Treatment for Retinopathy of Prematurity (ETROP) 
study,15 that is: (i) zone I, any stage of ROP, with plus 
disease; (ii) zone I, stage 3 ROP, with or without plus 
disease; or (iii) zone II, stage 2 or 3 ROP, with plus 
disease.10,11
 The traditional mainstay of treatment is laser 
photocoagulation to ablate all avascular areas and 
reduce the ischaemic stress to allow the retinal 
fibrovascular proliferation to regress.10,11 Intravitreal 
injection of anti–vascular endothelial growth factor 
(anti-VEGF) agent has recently been advocated 
if ROP is in zone I, stage 3 with plus disease 
or aggressive posterior ROP.16 Operation with 
vitrectomy or scleral buckle surgery is required if 
retinal detachment has occurred but the results are 
often unsatisfactory.17,18 Proper screening and timely 
treatment are thus important measures to prevent 
retinal detachment and vision loss. 
 The prevalence of ROP and severe ROP that 
requires treatment vary among different countries. 
The reported prevalence of ROP ranged from 12.6% 
to 44.5%13,19-23 and that of severe ROP requiring 
treatment ranged from 1.5% to 11.7% in other 
countries.13,19-23 In Hong Kong, studies that report 
the prevalence and severity of ROP are scarce.24,25 
The aim of this study was to evaluate the ROP 
prevalence, screening, and treatment outcome in a 
tertiary hospital in Hong Kong.
Methods
This was a retrospective cross-sectional study with 
internal comparison in which the medical records of 
eligible subjects were reviewed. All premature infants 
who were born at Queen Mary Hospital and had ROP 
screening performed between 1 January 2013 and 31 
December 2013 were included. In this hospital, all 
infants are screened if the British screening criteria 
are met—GA of <32 weeks or BW of <1501 g. Those 
who died before ROP screening could be performed 
were excluded from this study. This study was done 
in accordance with the principles outlined in the 
Declaration of Helsinki.
 All ROP screening was performed by two 
ophthalmologists who had experience in screening 
and treating ROP. All examinations were performed 
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with binocular indirect ophthalmoscopy following 
pupil dilatation by topical mydriatic medication. 
The severity of ROP was graded according to the 
revised International Classification of Retinopathy 
of Prematurity.14 The screening protocol followed 
the British Guidelines published in 200810:
•	 First	 ROP	 screening	 was	 performed	 at	 30	 to	
31 weeks postmenstrual age (PMA) for infants 
born before 27 weeks GA, and at 4 to 5 weeks 
postnatal age for infants born at or after 27 
weeks GA.
•	 Regular	 ROP	 screening	 was	 performed	 every	
1 to 2 weeks, and more frequent examinations 
at 1 week or less if the following features were 
present: (i) vascularisation ending in zone I or 
posterior zone II; (ii) presence of plus or pre-
plus disease; or (iii) presence of stage 3 ROP.
•	 Treatment	was	 initiated	within	 48	 to	 72	 hours	
if the ROP was type 1 pre-threshold defined by 
the ETROP study15 with the following features: 
(i) zone I, any stage of ROP, with plus disease; 
(ii) zone I, stage 3 ROP, with or without plus 
disease; or (iii) zone II, stage 2 or 3 ROP, with 
plus disease.
•	 ROP	screening	was	terminated	in	infants	who	did	
not develop ROP and in whom vascularisation 
had extended into zone III after 36 weeks PMA, 
or in those who developed ROP that did not 
meet treatment criteria and had subsequently 
regressed.
 Data recorded included GA, BW, presence 
of co-morbidities, most severe ROP stage, any 
treatment given, and the treatment outcome. If the 
ROP stage was asymmetrical between the two eyes 
in an individual infant, the more severe ROP stage 
was measured.
 Primary outcome measures included the 
prevalence of ROP of any stage and severe ROP that 
required treatment. Secondary outcome measures 
included association between risk factors of interest 
and risk of ROP development, and treatment 
outcome. The risk factors of interest studied included 
low GA, low BW, presence of respiratory distress 
syndrome (RDS), PDA, sepsis, NEC, IVH and the 
need for blood transfusion.
Statistical analysis
The Statistical Package for the Social Sciences 
(Windows version 23.0; SPSS Inc, Chicago [IL], 
US) was used to perform the statistical analysis. 
All continuous demographic data are expressed as 
mean ± standard deviation and categorical data are 
expressed as number (%). Further, GA and PMA are 
represented as number of weeks and the remaining 
days not completing a week written in superscript, 
eg 32 weeks and 5 days represented by 32+5 weeks. 
Chi squared test was used to evaluate the difference 
among subgroups for ROP development. Fisher’s 
exact test was used when the expected frequency of a 
cell in a table was <5. Risk factors that might predict 
ROP development were evaluated in univariate 
logistic regression analyses to calculate the odds 
ratio (OR) and 95% confidence interval. If there 
was more than one factor associated with a P value 
of <0.05 in univariate level, the risk factors would 
be entered into a multivariate logistic regression 
analysis with backward stepwise method. P<0.05 
was considered to be statistically significant. All tests 
were two-sided.
Results
Demographic data
A total of 92 infants met the British screening 
criteria during the study period of whom three died 
before ROP screening could be performed and were 
excluded from this study. Among the 89 infants 
screened, 52.8% were male. There were 49 (55.1%) 
singletons, 37 (41.6%) twins, and three (3.4%) triplets. 
The mean GA was 30+2 weeks ± 16.5 days (range, 
24+1 weeks to 35+5 weeks; median, 30+4 weeks). The 
mean BW was 1285 g ± 328 g (range, 580 g to 2030 g; 
median, 1340 g). The distribution of infants in 
relation to GA and BW is shown in Table 1.
Prevalence of retinopathy of prematurity
Of the 89 infants screened, 15 (16.9%) developed 
ROP at a mean time of 34+1 weeks ± 13.0 days (range, 
31+5 weeks to 38+4 weeks; median, 33+4 weeks), and 
three (3.4%) required treatment at a mean time 
of 40+2 weeks ± 9.6 days (range, 39+2 weeks to 41+6 
weeks; median, 39+5 weeks). Nine (10.1%) infants 
developed stage 1 ROP, three (3.4%) developed stage 
2 ROP, three (3.4%) developed stage 3 ROP, and none 
developed stage 4 or 5 ROP (Table 2).
 Among the 15 infants who developed ROP, 
their mean GA was 27+1 weeks ± 14.4 days (range, 
24+1 weeks to 30+2 weeks; median, 27+5 weeks) and 
mean BW was 846 g ± 276 g (range, 580 g to 1530 g; 
median, 790 g). 
 In subgroup analysis, among the 17 ELBW 
infants of <1000 g, 12 (70.6%) developed ROP and 
three (17.6%) required treatment. Among the 12 
extremely preterm infants with GA of <28 weeks, 
eight (66.7%) developed ROP and three (25.0%) 
required treatment (Table 2).
 When the 2013 American screening criteria 
were applied retrospectively, 78 (87.6%) infants met 
the criteria. In the 11 (12.4%) infants whose GA and 
BW exceeded the 2013 American screening criteria, 
none of them developed any ROP. 
Risk factors for development of retinopathy 
of prematurity 
In univariate logistic regression analysis, factors 
associated with risk of ROP development included 
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low GA (OR=1.129 for each day decrease; P<0.001), 
low BW (OR=1.007 for each g decrease; P<0.001), 
RDS (OR=4.952; P=0.044), PDA (OR=12.904; 
P<0.001), sepsis (OR=4.787; P=0.013), and need for 
blood transfusion (OR=11.786; P<0.001) [Table 3].
 In multivariate logistic regression analysis, 
factors associated with risk of ROP development 
included low BW (OR=1.006 for each g decrease; 
P<0.001) and PDA (OR=5.749; P=0.035) [Table 3].
Treatment of retinopathy of prematurity 
Three infants developed severe ROP that required 
treatment (Table 4). Their mean GA was 25+1 weeks 
± 7.5 days (range, 24+1 weeks to 26+2 weeks; median, 
25+1 weeks) and mean BW was 708 g ± 79 g (range, 
660 g to 800 g; median, 665 g). All received 
indirect diode laser photocoagulation treatment 
and all regressed after one laser treatment. No 
supplementary laser, intravitreal injection of anti-
VEGF agent, or surgery was necessary.
Discussion
This retrospective study identified the prevalence 
of ROP and severe ROP requiring treatment among 
premature infants in a tertiary hospital in Hong 
Kong. We observed a prevalence of ROP of 16.9% 
and that of severe ROP requiring treatment was 
3.4%. Our prevalence was comparable to or less than 
that reported in most other countries. The reported 
prevalences of ROP were 29.2% in Singapore,19 
37.8% in Southern Taiwan,20 21.6% in Southern 
India,21 12.6% in England,13 21.9% in Netherlands,22 
and 44.5% in Brazil.23 The reported prevalences of 
severe ROP requiring treatment were 4.8% to 5.0% 
in Singapore,19 11.7% in Southern Taiwan,20 6.7% 
in Southern India,21 1.5% in England,13 and 1.8% 
in Brazil.23 In mainland China, the ROP screening 
included bigger infants with BW of up to 2000 g and 
GA of up to 34 weeks, and the reported prevalences 
of ROP and severe ROP requiring treatment were 
17.8% and 6.8%, respectively.26 Since the risk of 
ROP among large infants is known to be small, the 
prevalence of ROP in mainland China could not be 
TABLE 1.  Demographic data of 89 infants who were screened 
for retinopathy of prematurity 
Demographics No. (%) of infants (n=89)
Gender
Male 47 (52.8)
Female 42 (47.2)
No. of gestations
Singleton 49 (55.1)
Twins 37 (41.6)
Triplets 3 (3.4)
Gestational age (weeks)
<26 5 (5.6)
26 to <28 7 (7.9)
28 to <30 19 (21.4)
30 to <32 41 (46.1)
≥32 17* (19.1)
Birth weight (g)
<1000 17 (19.1)
1000 to <1500 54 (60.7)
≥1500 18† (20.2)
* 17 Infants with gestational age of ≥32 weeks were screened 
because their birth weight was <1501 g
† 18 Infants with birth weight of ≥1500 g were screened 
because their gestational age was <32 weeks
* Fisher’s exact test
TABLE 2.  Outcome of retinopathy of prematurity (ROP) screening among 89 infants in relation to birth weight and gestational age
Outcome Birth weight (g) Gestational age (weeks)
<1000 
(n=17)
1000 to 
<1500 
(n=54)
≥1500 
(n=18)
P value* <28 
(n=12)
28 to <32 
(n=60)
≥32 
(n=17)
P value*
Any stage of ROP 12 (70.6%) 2 (3.7%) 1 (5.6%) <0.001 8 (66.7%) 7 (11.7%) 0 <0.001
Stage of ROP
Stage 1 6 (35.3%) 2 (3.7%) 1 (5.6%) 0.003 3 (25.0%) 6 (10.0%) 0 0.064
Stage 2 3 (17.6%) 0 0 0.006 2 (16.7%) 1 (1.7%) 0 0.067
Stage 3 3 (17.6%) 0 0 0.006 3 (25.0%) 0 0 0.002
Stage 4 0 0 0 1.000 0 0 0 1.000
Stage 5 0 0 0 1.000 0 0 0 1.000
Severe ROP requiring treatment 3 (17.6%) 0 0 0.006 3 (25.0%) 0 0 0.002
Aggressive posterior ROP 0 0 0 1.000 0 0 0 1.000
Retinal detachment 0 0 0 1.000 0 0 0 1.000
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directly compared with our study.
 Severe ROP is more prevalent in ELBW infants. 
Our study showed the prevalence of ROP was 
70.6% and that of severe ROP requiring treatment 
was 17.6% in ELBW infants of <1000 g. This was 
comparable to another local study in Hong Kong in 
which 53.4% of ELBW infants developed ROP and 
14.5% developed severe ROP requiring treatment.25 
Our results are also comparable to those of other 
countries, where the prevalences of ROP and severe 
ROP requiring treatment in ELBW infants were 
55.4% and 13.7% respectively in Singapore,19 70.7% 
and 29.3% respectively in Southern Taiwan,20 61.3% 
and 28.4% respectively in Northern Taiwan,27 
and 55.9% and 19.4% respectively in Turkey.28 
In this study, multivariate logistic regression 
analysis showed the risk of ROP development was 
significantly associated with low BW and presence 
of PDA. The association between PDA and risk of 
ROP development has been shown in previous 
studies.8,9 It has been postulated that persistent left-
to-right shunt results in low systemic blood flow 
and retinal ischaemia, and thus is associated with 
higher risk of ROP development.8,29 In addition, use 
of indomethacin to close PDA might reduce retinal 
blood flow and contribute to ROP development.8,30
 Dilated fundal examination in ROP screening 
is a stressful event for premature infants. It is 
important to screen only those who are at risk to 
avoid unnecessary examination and stress. In this 
study, 11 infants would not have been screened if 
the 2013 American screening criteria were used 
and none of them developed any ROP. This may 
suggest that the 2013 American Guidelines are more 
appropriate than the 2008 British Guidelines in 
reducing unnecessary examination.
 In our study, all severe ROP (100%) regressed 
after one laser treatment without the need for repeat 
treatment. No infants developed stage 4 or above 
ROP. This reflects a good standard of neonatal care in 
TABLE 3.  Univariate and multivariate logistic regression analyses of risk factors in relation to development of retinopathy of 
prematurity of any severity among 89 infants screened
TABLE 4.  Characteristics and outcome of infants who received treatment for retinopathy of prematurity
Odds ratio 95% Confidence interval P value
Univariate
Low gestational age (days) 1.129 1.067-1.194 <0.001
Low birth weight (g) 1.007 1.004-1.010 <0.001
RDS 4.952 1.043-23.523 0.044
PDA 12.904 3.547-46.949 <0.001
Sepsis 4.787 1.388-16.515 0.013
NEC 3.000 0.770-11.682 0.113
IVH 1.135 0.224-5.738 0.878
Blood transfusion 11.786 3.265-42.548 <0.001
Multivariate
Low gestational age (days) (Excluded from multivariate logistic model)
Low birth weight (g) 1.006 1.003-1.009 <0.001
RDS (Excluded from multivariate logistic model)
PDA 5.749 1.129-29.271 0.035
Sepsis (Excluded from multivariate logistic model)
Blood transfusion (Excluded from multivariate logistic model)
Patient 
No.
Gestational 
age (weeks)
Birth 
weight (g)
Severity of ROP and time of development Types and time of treatment Outcome
1 24+1 660 BE zone 2, stage 3, with plus disease at PMA 41+4 weeks BE laser at PMA 41+6 weeks ROP regressed
2 26+2 800 BE zone 2, stage 3, with plus disease at PMA 38+6 weeks BE laser at PMA 39+2 weeks ROP regressed
3 25+1 665 BE zone 2, stage 3, with plus disease at PMA 39+5 weeks BE laser at PMA 39+5 weeks ROP regressed
Abbreviations: IVH = intraventricular haemorrhage; NEC = necrotising enterocolitis; PDA = patent ductus arteriosus; RDS = 
respiratory distress syndrome
Abbreviations: BE = both eyes; PMA = postmenstrual age; ROP = retinopathy of prematurity
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Hong Kong. In Southern Taiwan, 16.9% progressed 
to stage 4 or 5 ROP requiring further intervention 
after initial treatment.20 In mainland China, 4.2% 
of stage 3 ROP and 28.6% of aggressive posterior 
ROP progressed to retinal detachment after initial 
treatment.26
 Our study highlights the importance of proper 
screening and timely treatment to prevent retinal 
detachment and severe vision loss due to ROP. 
We recommend strict adherence to international 
screening guidelines, and all ROP screening should 
be performed by ophthalmologists with dilated 
fundal examination.10 Since ELBW infants have 
a high risk of ROP and need for treatment, early 
parent education and good communication with 
anticipation for treatment will be helpful. For 
premature infants transferred from other hospitals 
for non-ophthalmological conditions, attention 
should be paid to the ROP screening record and 
examinations should be performed if the screening 
criteria are met. Good communication between 
hospital units is crucial to ensure continuous care 
and that these infants do not miss ROP screening 
and thus the window of opportunity for treatment.
 There were several limitations in this study. 
First, the sample size was small. Second, due to 
the retrospective design, this study was not able 
to evaluate other potential risk factors that might 
increase the risk of ROP development. The level of 
oxygen therapy was not evaluated because it could 
not be assessed accurately in view of frequent 
changing of arterial oxygen saturation level and 
percentage of oxygen administered. Last, this study 
reviewed only those who had received ROP screening 
or treatment, therefore we were not able to evaluate 
those who died before being screened.
Conclusions
Retinopathy of prematurity is an important health 
problem among premature infants in Hong Kong, 
especially those with ELBW. The results of our 
study suggest that the current screening service 
and treatment outcome are satisfactory. Strict 
adherence to international screening guidelines and 
vigilance in infants at risk are key to successful ROP 
management.
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